The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Conversely, p53 function is altered or attenuated in one way or another in the majority of human cancers. Besides its well-understood action as a transcriptional regulator of multiple apoptotic genes, p53 also exerts a direct pro-apoptotic role at the mitochondria by engaging in protein-protein interactions with anti-and pro-apoptotic Bcl2 family members, thereby executing the shortest known circuitry of p53 death signaling. Nur77, also known as TR3 or NGFI-B, is a unique transcription factor belonging to the orphan nuclear receptor superfamily. Even more extreme than p53, Nur77 can exert opposing biological activities of survival and death. Its activities are regulated by subcellular distribution, expression levels, protein modification and heterodimerization with retinoid X receptor. In cancer cells, Nur77 functions in the nucleus as an oncogenic survival factor, but becomes a potent killer when certain death stimuli induce its migration to mitochondria, where it binds to Bcl2 and conformationally converts it to a killer that triggers cytochrome c release and apoptosis. This review focuses on their unexpected transcription-independent pro-death programs at mitochondria and highlights the remarkable mechanistic similarities between them. Moreover, an accumulating body of evidence provides ample rationale to further investigate how these mitochondrial p53 and Nur77 pathways could become exploitable targets for new cancer therapeutics.
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The p53 tumour suppressor is a crucial protector against cancer by eliminating cells with mutagenic alterations or by blocking their cell cycle permanently or transiently by allowing DNA repair. The powerful apoptotic function of p53 -pleiotropic in its nature -is central to its antineoplastic activity. p53 responds to death stimuli by rapid stabilization and activation. It mediates apoptosis primarily via the mitochondrial pathway. p53 can act as a transcription factor to stimulate the expression of proapoptotic target genes like Puma, Noxa, Bax, Bid, p53AIP1 and many others, often in a cell-and stresstype preferred way (Vousden and Lu, 2002) . p53 can also mediate transrepression of anti-apoptotic genes such as Bcl2 and survivin. Moreover, complex negative feedback influences exist among p53's multiple generegulatory functions that impact on the final biological outcome of the DNA stress response. For example in lethally irradiated hematopoietic progenitor cells p53 transactivates the transcriptional repressor Slug that in turn then directly represses the p53-mediated transcription of Puma (Wu et al., 2005) .
Multiple death signals induce mitochondrial translocation of p53 with rapid kinetics
The mitochondrial death pathway plays a pivotal role in p53-dependent apoptosis (Schuler and Green, 2001 ). In the last 5 years solid evidence was gathered that in addition to the varied gene-regulatory mechanisms, p53 translocation to mitochondria with direct outer membrane permeabilization is a common early component in p53-mediated apoptosis The earliest reports of a transcription-independent killing action of p53 came from seeing unimpeded apoptosis despite pharmacological inhibition of transcription or translation in strictly p53-dependent cellular death systems. Apoptosis after overexpression of transactivation-deficient p53 mutants in null cells supported to this notion. While a mechanistic understanding for these p53 effects were lacking for a long time, this was rapidly changed in 2000 with the discovery that a fraction of stress-stabilized wild-type p53 (wtp53) protein traffics to mitochondria at the onset of p53-dependent apoptosis (Marchenko et al., 2000) .
Stress-induced mitochondrial p53 accumulation occurs in many cellular systems. It takes place in radiosensitive tissues such as thymus, spleen and testis in vivo (Erster et al., 2004) . It also occurs in cultured primary cells like mouse thymocytes, human mammary epithelial (HMEC), umbilical vein endothelial (HUVEC) cells, dermal fibroblasts and skin keratinocytes (Mihara et al., 2003; Bonafe et al., 2004; Nemajerova et al., 2005b; Zhao et al., 2005) , as well as in immortal and transformed cell lines of all three germ lines (Marchenko et al., 2000; Sansome et al., 2001; Dumont et al., 2003; Leu et al., 2004; Arima et al., 2005) .
The phenomenon is induced by many different stress signals: DNA-damaging agents including chemotherapeutics, UV and g-IR; hypoxia, viral and cellular oncogenes, transcriptional blockade and reactive oxygen species-generating agents (Marchenko et al., 2000; Sansome et al., 2001; Mihara et al., 2003; Arima et al., 2005; Nemajerova et al., 2005b; Zhao et al., 2005) . On the other hand, mitochondrial p53 translocation does not occur in p53-independent death via for example the TNF pathway, although mitochondria are also downstream components of the TNF/DISC/procaspase-8 pathway (Marchenko et al., 2000) . Of note, stable overexpression of BclXL and Bcl2 in myeloid progenitor cells (32D) inhibits DNA damage-induced p53 mitochondrial translocation (but not its overall cellular stabilization) as well as p53-dependent apoptosis, while both events do occur in vector control cells (Marchenko et al., 2000) . This was an early hint at the molecular targets of p53 at the mitochondria (see below).
Further support for an apoptotic function of mitochondrial p53 came from the study of a common polymorphism (Arg/Pro at codon 72) of human p53 (Dumont et al., 2003; Leu et al., 2004) . In a series of engineered isogenic SaOs2 cell lines as well as in homozygous Arg and Pro melanoma lines, the Arg version of p53 consistently shows five to 10 fold higher apoptotic ability. This differential apoptotic activity strongly correlates with their differential abilities to localize to mitochondria, but not with their transcriptional and transrepressor abilities nor their abilities to bind to Mdm2. The differences in the apoptotic potentials of the Arg/Pro p53 variants are eliminated when these proteins were coupled to a leader sequence that directs both p53 variants equally well to mitochondria (see below) (Dumont et al., 2003) . Of note, further functional in vivo relevance of the codon 72 polymorphism is provided by an Italian study of a group of old patients (66-99 years of age) affected by acute myocardial ischemia (Bonafe et al., 2004) . Compared to Pro patients, Arg patients show increased levels of Troponin I and CK-MB (creatin kinase-muscle brain isoenzymes), two serum markers that correlate with the extent of the ischemic damage. Moreover, in response to oxidative stress fibroblasts and lymphocytes from Arg/Arg individuals have a higher level of mitochondrially localized p53 and p53/BclXL complexes and accordingly, undergo a higher rate of apoptosis than Pro/Pro individuals, especially seen in old people. Together, these data provide support that differences in the apoptotic potential of the two variants, mediated by their differential ability to target to mitochondria, contributes to a genetically determined variability in apoptotic susceptibility among older people in the context of myocardial ischemia (Bonafe et al., 2004) .
Mitochondrial p53 translocation occurs with fast kinetics. For example, in cells of hematopoietic and lymphopoietic lineage this occurs within 30-60 min after the initial stress stimulus and prior to detectable nuclear accumulation (Marchenko et al., 2000; Sansome et al., 2001; Mihara et al., 2003; Erster et al., 2004; Zhao et al., 2005) . p53 translocation precedes cytochrome c release from the mitochondrial intermembranous space, the collapse of the inner mitochondrial membrane potential and procaspase-3 activation (Marchenko et al., 2000) . In radiosensitive organs (such as thymus, spleen and testis) but not radioresistant organs (such as liver and kidney) from normal mice treated with a single clinical dose of g-irradiation or etoposide, mitochondrial p53 translocation triggers rapid caspase-3 activation and apoptosis in a subpopulation of cells. Of note, in thymus this precedes the transcriptional induction of Puma, the fastest known apoptotic target gene of p53 and most relevant in this setting (i.e. irradiated thymus) (Erster et al., 2004) . This suggests that the mitochondrial pathway also participates in tumor suppression in vivo.
Localization of mitochondrial p53
Like several other famous mitochondrial proteins (i.e. cytochrome c), p53 lacks classical mitochondrialtargeting sequences. Yet, mitochondrial p53 is primarily localized at the outer mitochondrial membrane (OMM), as demonstrated by immunogold electron microscopy and controlled trypsin digestion of mitochondria isolated from stressed cells. The majority of stress-translocated mitochondrial p53 is trypsinsensitive and digested with the same rapid kinetics (10 min) as the prototypical OMM protein BclXL, while cytochrome c in the intermembranous space is protected (Marchenko et al., 2000; Sansome et al., 2001) . A small subfraction of translocated p53, however, is trypsin resistant, indicating an intramitochondrial localization in the matrix (see below) (Achanta et al., 2005; Zhao et al., 2005) . This result is supported by the detection of stress-inducible endogenous complexes between p53 and the major mitochondrial import proteins localized in the mitochondrial matrix, mt hsp70 and mt hsp60 (the ATP-hydrolysing endopeptidases responsible for refolding imported proteins) (Marchenko et al., 2000; Dumont et al., 2003; Kaul et al., 2005) .
The precise signal on p53 for its mitochondrial translocation remains to be defined. A translocation motif within the p53 amino-acid sequence was not found and phosphorylation/acetylation modifications of p53 are not determinants for mitochondria translocation (Nemajerova et al., 2005a) . Studies on the Arg/Pro codon 72 variants proposed that Mdm2-mediated polyubiquitylation of p53 mediates nuclear export and mitochondrial translocation (Dumont et al., 2003) , but this area requires more work for a better understanding.
p53 and Nur77/TR3 UM Moll et al p53 permeabilizes the outer mitochondrial membrane and induces the release of potent apoptotic activators like cytochrome c, SMAC and AIF Nuclear bypass experiments in cultured p53 null cells first proved causality and revealed the functional consequences between mitochondrial p53 and the induction of apoptosis (Marchenko et al., 2000; Talos et al., 2005) . Various p53 fusion proteins with mitochondrial targeting motifs at its N-or C-terminus efficiently delivered p53 to mitochondria while being devoid of any detectable nuclear transcriptional function. The first mitochondrial targeting motif used for wtp53 was the prototypical import leader of human ornithine transcarbamylase (the fusion was called Lp53wt) (Marchenko et al., 2000) . More recently, targeting motifs derived from the transmembrane domains of Bcl2 and BclXL (called p53CTM and p53CTB, respectively) were employed to target p53 directly to the OMM (Mihara et al., 2003; Talos et al., 2005) . The targeted p53 proteins are undetectable in nuclei of transfected cells, suggesting a lack of transcriptional activity. This was confirmed by sensitive luciferase reporter assays driven by concatamerized consensus p53-binding elements or the endogenous p53-responsive promoters of PUMA and PIG3. Moreover, mito-targeted p53 failed to induce endogenous p53 target genes of the apoptotic and arrest categories, including Noxa, Bax and p21Waf1 (Mihara et al., 2003) . When delivered to p53-null human and mouse tumor cell lines in culture, the apoptotic ability of these targeted p53 versions is generally comparable although somewhat weaker than conventional nuclear p53 (Mihara et al., 2003; Talos et al., 2005) . This is seen after transfection (supraphysiologic levels) into lung carcinoma H1299 and osteosarcoma SaOs2 cells as well as with physiological expression levels after retroviral transduction in primary B-lymphoma cells. Moreover, mitochondrially targeted p53 is able to suppress growth in long-term colony suppression assays in several p53 null cancer lines (Mihara et al., 2003) . In contrast, the transcription factor c-Rel, when targeted to mitochondria using the same L-motif, has only background apoptotic activity (Marchenko et al., 2000) . Conversely, wtp53 targeted to the endoplasmic reticulum (via the leader sequence of cytochrome b5) is devoid of any apoptotic activity (Talos et al., 2005) . The C-terminus of p53 harbors the tetramerization domain, several nuclear localization and a nuclear export signal, as well as multiple post-translational regulatory sites for protein stabilization and activation that are critical for p53's function as a transcription factor. Of note, this region is fully dispensable for p53's mitochondrial action (Marchenko et al., 2000) , a fact that might potentially become of future therapeutic relevance by escaping dominant negative interference by tumor-overexpressed mutant p53 or delta Np63/p73 isoforms (see below). Together, these results clearly indicate that, although not as efficient as nuclear p53, mitochondrial p53 alone is sufficient to launch apoptosis and growth suppression directly from the mitochondria, thus runs a direct mitochondrial death program in parallel to its nuclear action. The fact that 'conventional' p53 commands both the nuclear and the mitochondrial death programme explains why it is more potent than the forcibly targeted p53.
This pro-apoptotic action of mitochondrial p53 is due to its autonomous ability to permeabilize the outer mitochondrial membrane, without the need for addition of any other protein. This was definitively shown in vitro in classic release assays on freshly isolated unstressed mitochondria from mouse liver, originally introduced for the prototypical Bax and Bak proteins. When added, highly purified recombinant wtp53 protein (without any targeting motifs), but not the C-terminus of p53 or another irrelevant purified protein, induces the robust and rapid release of mitochondrial cytochrome c, Smac/ Diablo, endonuclease G and apoptosis inducing factor (AIF) from the intermembranous space. This occurs rapidly and is dose-dependent. After 5 min, 70% of the total cytochrome c content is released and within 30 min the process is complete (Mihara et al., 2003; Leu et al., 2004) (Moll et al., unpublished results) . Mouse or human p53 protein of bacterial or baculoviral origin work equally well in these assays. The latter indicates that once delivered, posttranslational modifications of p53 are not involved in regulating its mitochondrial permeabilization function (Nemajerova et al., 2005a) .
Three interrelated mitochondrial p53 arms
Wild type but not tumor-derived mutant p53 directly binds to and antagonizes the anti-apoptotic BclXL and Bcl2 proteins Mitochondrial wtp53 engages in inhibitory complexes with anti-apoptotic BclXL and Bcl2 proteins, as shown by biochemical, mutational, molecular modeling, structural and biophysical studies (Mihara et al., 2003; Bonafe et al., 2004; Leu et al., 2004; Petros et al., 2004) (Moll et al., unpubl. results) . This makes eminent sense since the protective Bcl2 and BclXL proteins are constitutively anchored at the OMM and mediate a critical survival function by stabilizing the OMM and inhibiting the release of cytochrome c and other apoptogenic factors. Bcl2 and BclXL are the closest structural and functional homologues in the Bcl2 family with 45% sequence identity and 56% similarity, including their strong anti-apoptotic functions and their affinities to bind BH3-only proteins (Petros et al., 2001) . The expression levels of the two proteins in cells are also interrelated, that is the overexpression of one represses the other (Arriola et al., 1999) . In wtp53-expressing cells exposed to short-term DNA damage, specific endogenous p53/BclXL and p53/Bcl2 complexes form at purified mitochondria (which are free of nuclear contamination). These complexes are readily detectable by standard co-immunoprecipitations in CHAPS or NP40-containing buffers, by immunoaffinity chromatography and by co-purification in glycerol gradients, both from stressed cells and from isolated unstressed mitochondria after incubation with p53 protein. Complexes are enriched in the mitochondrial membranes compared to the soluble mitochondrial fraction. They are also formed between exogenously expressed components upon transfection in p53 null cells. A direct interaction between p53 and BclXL was confirmed by in vitro pull down assays of recombinant components. In contrast, a p53/Bax complex is never detectable, even after triple transfection of targeted p53, BclXL and Bax, and Bax is unable to interfere with the formation of p53/BclXL (Mihara et al., 2003) .
Mutational structure/function studies and protein modeling using a novel docking algorithm predicted that the DNA-binding domain of p53 mediates the interaction with BclXL and Bcl2. The p53 DNA-binding domain with its overall basic character interacts with the overall acidic 'bottom side' of BclXL. This BclXL site is opposite from the hydrophobic binding groove formed by BH1, BH2 and BH3 domains that accept BH3-domain containing proteins and is composed by the a1 helix/BH4 domain plus additional downstream domains of BclXL. Of note, in agreement with the consistent inability to detect stable p53/Bax complexes (Mihara et al., 2003; Chipuk et al., 2004) , the corresponding underside of Bax (nor of Bak, see below) do not feature acidic domains capable of binding p53. Structure/ function deletion and site-directed mutagenesis studies revealed that the major contact site on p53, comprised of residues 239-248 (part of the L3 loop), is flanked by two lateral domains on either side, contributed by residues 135-141 (L1 loop) and residues 173-187 (part of L2 loop and H1 helix) (Mihara et al., 2003) . Deletion of the aa239-248 region in the context of targeted L-wtp53 completely abolishes BclXL complexes as well as apoptosis and colony growth suppression. Deletion of any of the flanking regions produces an intermediate phenotype in any of these three functions. Together, this indicates that p53/BclXL complex formation is required for p53-mediated OMM permeabilization.
Structural and biophysical studies subsequently validated the predicted interaction sites and determined their affinities. Solution NMR spectroscopy studies by Fesik et al., and later by our group experimentally determined the p53/BclXL (Petros et al., 2004) (Moll et al., unpublished) and p53/Bcl2 interactions (Moll et al., submitted) . The isolated DNA-binding domain of bacterially expressed human wtp53 and various versions of BclXL or Bcl2 (with or without their transmembrane domains and the long loop between BH4 and BH3) were used. Neither p53 nor BclXL or Bcl2 undergo major conformational changes upon binding. The chemical shift changes on p53 caused by the BclXL interaction are at residues Arg-280, Cys-277, Ser-241, Cys-238, Cys-182 and Val-173 of the DNA contact surface. The reciprocal changes on BclXL upon p53 addition are on residues in the C-terminal end of the BH4 domain and the two loops between the a3 and a4 helix and the a5 and a6 helix (Petros et al., 2004) (Moll et al., unpublished) . For the p53/Bcl2 complex, the affected p53 residues were partly distinct but again within the DNA contact site (Moll et al., submitted) . The affinities of the physical interactions between BclXL/Bcl2 and wtp53, quantitated by surface plasmon resonance studies (BIAcore), lie in the hundred nanomolar ranges and are consistent with immunoprecipitable endogenous complexes. Bcl2 interacts with wtp53DBD with a K D1 ¼ 535724 nM (Moll et al., submitted) . A slightly stronger affinity is reported for full-length wtp53 and BclXL (K D ¼ 164754 nM) .
Importantly, these studies imply that the DNAbinding domain of p53 is a 'dual-function domain', mediating both the transactivation and the direct mitochondrial pro-apoptotic function. Moreover, in cytochrome c release assays from unstressed mitochondria OMM permeabilization by wtp53 is dependent upon p53/BclXL complex formation. This prediction was studied with tumor-derived missense mutants of p53 in vitro and within cells. Indeed, all tested tumor-derived and transactivation-deficient missense mutants of p53 concomitantly lose or severely compromise their ability to interact with BclXL and Bcl2, as well as to promote OMMP. Thus, tumor-derived p53 mutations may represent a positive selection of 'double hits', eliminating the transcriptional as well as the direct mitochondrial functions of p53 (Mihara et al., 2003) (Moll et al., submitted) . Conversely, the mechanism of mitochondrial wtp53 involves BH3-only like actions of derepression or 'enabling', that is inhibiting the anti-apoptotic Bcl2 members . By engaging in inhibitory complexes with protective Bcl2 and BclXL, p53 indirectly activates pro-apoptotic executioner BH123 proteins like Bak and Bax by freeing them (see below).
p53 directly activates the apoptotic effector Bak in the OMM
In addition to this indirect mechanism, a second interaction target of mitochondrial p53 is Bak itself, a critical effector BH123 protein of the OMM. Here, direct binding of p53 to Bak yields its homo-oligomerization and activation. This was first seen in vitro: when added to unstressed mitochondria, purified p53 protein induced homo-oligomerization of endogenous Bak, detectable by cross-linkers. p53 is at least as efficient as the prototypical BH3-only protein tBid (Mihara et al., 2003) . The precise mechanism involves a musical chair scenario: in healthy cells, Bak is kept inactive by complexing with the anti-apoptotic Mcl-1 or BclXL in the OMM. Bak induces apoptosis only if freed from both . Upon stress, p53 translocates to mitochondria and liberates pro-apoptotic Bak from its sequestration by Mcl-1 by forming a p53/Bak complex, thus promoting Bak oligomerization (Leu et al., 2004) . Treatment of isolated unstressed mitochondria with recombinant p53 protein reduces the amount of immunoprecipitable Mcl-1/Bak complexes and reciprocally increases the amount of p53/Bak complexes. Moreover, addition of p53 to Bak þ / þ mitochondria, but not BakÀ/À mitochondria isolated from mouse embryo fibroblasts induces OMM in vitro (Dumont et al., 2003) . We confirmed the existence of specific p53/ p53 and Nur77/TR3 UM Moll et al Bak complexes in stressed cells (Moll UM et al., unpublished) . Deletion mapping narrowed the region of the Bak-interaction site on p53 to residues 92-160, thus distinct from the site used for contacting BclXL and Bcl2 but again within the DNA-binding domain (Leu et al., 2004) . More work needs to be carried out to better understand the significance of the p53/Bak complex. For example, its structure waits to be solved experimentally. As Bak is lacking a BH4 domain as well as acidic residues in the loops between a3 and a4, its structure likely differs from that of the p53/BclXL complex. Also, the impact of p53 missense mutations on the ability to form a Bak complex has not been tested. The physiological significance of the p53-mediated Bak liberation from Mcl-1 sequestration as proposed in this model poses interesting questions, since Mcl-1 is unique among the pro-survival Bcl2 members. In contrast to BclXL and Bcl2, Mcl-1 has a short half-life and its expression levels are highly regulated. It is rapidly induced by a wide range of survival signals, but also rapidly downregulated during apoptosis by proteolysis, mediated by the E3 ubiquitin ligase Mule/ARF-BP1, caspases and other proteases (Zhong et al., 2005) . This might obviate the need for a p53-mediated liberation of Bak in many circumstances. Stable Mcl-1 expression, however, is required for embryonic development and for the homeostasis of immune and hematopoietic systems, as shown by knockout studies. Thus, mitochondrial p53-mediated Bak liberation might be particularly important in those cell systems.
p53 can directly activate cytosolic Bax
A third transcription-independent p53 arm was described in UV-treated transformed mouse embryonic fibroblasts, representing those cell types that express a subfraction of BclXL in the cytosol (Chipuk et al., 2004 . Here, p53's primary action lies in activating cytosolic Bax by liberating it from sequestration by cytosolic BclXL, with p53 binding to BclXl instead. The major BclXL fraction resides in the OMM (Kaufmann et al., 2003; Gonzalez-Garcia et al., 1994) . Bcl2 is exclusively membrane-bound and does not participate in this arm (Hsu et al., 1997) ). Cytosolic p53 activates monomeric Bax by inducing its homo-oligomerization (and presumed mitochondrial translocation) in a proposed 'hit and run' mechanism that does not involve stable p53/Bax complexes (Chipuk et al., 2004) . Transcription-independence of this p53 action in this UV fibroblast system was extensively demonstrated, using protein synthesis inhibitors, nuclear import inhibition (wheat germ agglutinin), enucleated cytoplast preparations and a transcription-deficient p53 mutant (QS) (Chipuk et al., 2004) . In contrast to the previous two arms relying on the p53 DBD, here the N-terminus of p53, comprising only the first 102 amino acids, is sufficient to mediate Bax activation and apoptosis. Conversely, deletion of the polyproline-rich domain (PP, 62-91) from p53 abolishes p53's ability to displace prebound Bid or Bax from BclXL and to activate recombinant Bax in vitro, mapping this function to the PP domain (Chipuk et al., 2004) . To what degree the PP and the DBD domains of p53 cooperate in their overall mitochondrial function is unknown but it is tempting to speculate that each function is mediated by a separate domain. Similar conclusions on the general importance of transcription-independent apoptotic p53 function were drawn from studies in mouse fibroblasts NIH3T3. Upon low-dose UV-irradiation the primary, transcription-mediated p53 response is terminal growth arrest. High-dose UV-irradiation induces apoptosis. Induction of p53-dependent apoptosis requires an additional, transcription-independent p53 activity provided by high cytoplasmic levels of activated p53, and correlates with Bax activation (Speidel et al., 2005) . Subsequent work by Chipuk et al. (2005) expanded the cytosolic p53 model to integrate both transcriptionindependent and transcription-dependent functions of p53. The proposal is that stress-induced cytosolic p53 is initially sequestered into an inactive complex by cytosolic BclXL. In a second phase, which requires the p53-mediated transactivation of its target gene PUMA, p53 is then liberated from this cytosolic BclXL embrace by a newly formed PUMA/BclXL complex. Liberated p53 can then directly activate Bax. This model is based on work in UV-treated fibroblasts and HCT116 colon carcinoma cells using high doses of UV (up to 4000 J/m 2 ) and rests upon the phenotype of a mutant of BclXL that still binds p53, but not PUMA (BclXL G138A, which does not bind to proapoptotic BH3-only and BH123 proteins). While expression of wild-type and mutant BclXL suppressed p53-mediated apoptosis, additional overexpression of Puma only reversed the effect of wildtype BclXL, suggesting that in this system p53 needs to be released from Puma to activate Bax. Some open questions are how to integrate into this model their earlier results stressing transcription-independence of Bax activation by cytosolic p53 (Chipuk et al., 2004) , its precise Bax activation mechanism and whether PUMA is absolutely required for the extranuclear activity of p53. Evidence from our lab indicates that at least the mitochondria-based death function of p53 is autonomous and does not require Puma (Moll et al., unpublished) . Also, functional overlap with mitochondrial action can be envisioned: likely, liberated p53, either before or after its transient encounter with Bax, also translocates to mitochondria to act as described above. Moreover, this model does not preclude that transactivated Puma also liberates p53 from its BclXL embrace at mitochondria, which then activates Bax and Bak within the OMM.
Importantly, while distinct in details, there is a common mechanistic theme underlying all three arms of extranuclear p53 ( Interestingly, the short H2 helix of p53 close to the C-terminal end of the DBD shows a remarkable sequence homology to the BH3 consensus motif (Mihara et al., 2003) . Phsyiologically, the nuclear, mitochondrial and cytoplasmic functions of p53 are likely to cooperate, thereby integrating into the full force of p53-mediated apoptosis.
The stress-induced direct mitochondrial p53 death program: its role in physiologic and pathophysiologic responses in vivo after genotoxic, hypoxic and oxidative damage.
The direct mitochondrial p53 program participates in the overall apoptotic p53 response physiologically: normal mice were subjected to a single dose of 5 or 10 Gy whole body g-irradiation or a single clinical dose of intravenous etoposide. Mitochondrial p53 accumulation occurred in radiosensitive organs like thymus, spleen, testis and brain, but not in radioresistant organs like liver and kidney that undergo a strictly nuclear accumulation leading to cell cycle arrest.
Careful kinetic analysis of the mitochondrial versus the transcriptional p53 pathway in thymus show that mitochondrial events are ahead of transcriptional events, confirming that the mitochondrial p53 pathway participates in the overall p53 stress response of radiosensitive organs. Mitochondrial p53 translocation is rapid (within 30 min after IR in thymus and spleen) and triggers an early wave of caspase-3 activation and apoptosis. This caspase-3-mediated apoptosis is strictly p53 dependent and precedes p53 target gene activation. In 5 Gy irradiated thymus at the 1 h time point, mitochondrial p53 accumulation is already very robust and coincides with cleaved caspases in a fraction of cells (leading to TUNEL positivity by 2 h). In contrast, total cellular and nuclear p53 only begins to be induced at that time (and peaks only at 3 h). Accordingly, the transcriptional p53 program has a longer lag phase than the rapid mitochondrial p53 program. In thymus, PUMA is the earliest and physiologically most relevant p53 product in this setting (Erlacher et al., 2005) . However, PUMA induction occurs within a sharp time window between 2 and 3 h (with decline thereafter), leading to another boost in caspase-3 activation. The p53 target Noxa appears transiently at the 4 h and Bax only very late at the 8 h time point (which coincides with a 100% TUNEL positivity), while other p53 targets such as Bid, Killer/DR5, and p53DinP1 remain uninduced even after 20 h. Similar biphasic kinetics is seen in wtp53 expressing cancer cell lines (ML1 and RKO) after genotoxic stress. Together, these results provide evidence that in sensitive organs and cells the mitochondrial p53 program occurs soon after a death stimulus in vivo, triggering a rapid first wave of transcription-independent apoptosis which may precede a second slower wave that is transcriptiondependent. Evidence for the in vivo significance of this program is also provided by a number of pathophysiologic studies in animals and primary cells. In the context of mycocardial infarction, the correlation between a genetically determined variability in cell death susceptibility and p53 codon 72 variants with their differential mitochondrial localization was already described above (Bonafe et al., 2004) . Another important setting in which apoptosis is largely mediated by the mitochondrial p53 program is ischemia-reperfusion injury of the kidney, leading to acute renal failure (Kelly et al., 2003) , a common clinical problem. In ischemia, the outer medulla, composed of two types of tubules, exhibits p53-independent necrosis of the proximal straight tubules and p53-dependent apoptosis of the thick ascending tubules. Both components independently contribute to renal failure. Acute renal failure is experimentally modeled by transient bilateral renal artery occlusion in rats. Importantly, ischemia-induced stabilization of p53 protein in the outer medulla is to a large extent mitochondrial and this mitochondrial p53 translocation correlates with apoptosis of tubular cells in vivo (Kelly et al., 2003; Dagher, 2004) . Likewise, in primary proximal tubular epithelial cells after chemical anoxia with antimycin A, mitochondrial p53 translocation is prominent (and triggered by GTP depletion as intracellular mediator of death stimulus) (Kelly et al., 2003) . Notably, pifithrin-a, a selective and potent p53 inhibitor (Komarov et al., 1999) , prevents tubular apoptosis in the outer medulla and protects renal function in the animal. The protective effects of pifithrin-a involved both downregulation of the transcriptional activation of Bax and a direct inhibition of p53 translocation to mitochondria (Kelly et al., 2003) . Likewise, in cultured tubular cells after antimycin A anoxia, pifithrin-a also blocks mitochondrial p53 translocation and apoptosis (Kelly et al., 2003) .
In primary cultures of rat embryonal astrocytes and C6 glioma cells subject to oxidative stress, similar events occur. When treated for 1 h followed by 24 h recovery, low levels of p53 are restricted to the nucleus until the end of the short stress period. During the following 6-24 h recovery period, p53 levels continue to rise, with its subcellular distribution becoming largely mitochondrial. Concomitant with mitochondrial p53 targeting, mitochondria undergo profound structural alterations from healthy filamentous mitochondria to fused, coarsened 'megamitochondria' starting at 3 h recovery. This morphologic hallmark of early apoptosis coincides with increasing cytochrome c release and subsequent nuclear fragmentation by 12-24 h (Bonini et al., 2004) .
Another site where the mitochondrial p53 program appears to play a role in vivo are the synaptic terminals of neurons in the brain cortex during DNA damageinduced neuronal death. In a model using topical etoposide on anesthetized mouse brain, isolated neuronal synaptosomes exhibit higher levels of total p53 and phosphoSer15-p53 than the distal cell bodies. This synaptic p53 facilitates the collapse of the mitochondrial membrane potential and ROS production upon additional oxidative and excitotoxic insults. Synaptosomes of p53À/À mice show a significantly lower degree of these changes. Conversely -and as already seen above in renal tubular cells -pretreating synaptosomes with pifithrin-a preserves their mitochondrial membrane potential and partially blocks ROS production. Also, in cultured primary hippocampal neurons p53 becomes detectable in presynaptic terminals after etoposide exposure. This coincides with synaptic degeneration and again can be prevented by pifithrin-a pretreatment (Gilman et al., 2003; Culmsee and Mattson, 2005) . Synaptic degeneration is thought to be a critical initial event for acute and chronic neurodegenerative diseases including stroke, Alzheimer's, Parkinson's and Huntington's disease.
Together, these studies support a role for the direct mitochondrial p53 pathway in vivo. But further work along these lines, ideally in relevant animal models is needed to fully define the extent of this program in physiologic and pathophysiologic responses to genotoxic, hypoxic and oxidative insults.
Possible implications for cancer therapy
Abrogation of p53-mediated apoptosis is a fundamental defect enabling the formation of human tumors. In addition, mutant p53 in tumors promotes chemoresistance, thus confounding the success of cancer therapy. Hence, its functional restoration is a premier therapeutic goal in clinical oncology.
As discussed above, p53 forcibly targeted to mitochondria is devoid of transcriptional activity but is sufficient to induce apoptosis in a transcription-independent fashion in p53-null human cancer cell lines. Thus, mitochondrial targeting of p53 at least partly phenocopies nuclear p53 in launching effective apoptosis and long-term growth inhibition. In an important step towards therapeutic exploitation, we showed that the direct mitochondrial p53 program exerts a significant tumor suppressor activity in Em-Myc transgenic mice, a well-established transplantable model of human Burkitt's lymphoma and p53-dependent lymphomagenesis (Talos et al., 2005) (Figure 2) . In Em-Myc lymphomas of p53-deficient or ARF-deficient genotypes, exclusive delivery of p53 to the outer mitochondrial membrane (by using p53 proteins fused to the transmembrane domain of BclXL or Bcl2) confers efficient apoptosis and markedly inhibits cancer growth in vivo. When present as the sole source of functional p53, these p53 fusions, which lack residual transcriptional activity, possess an apoptotic potency that is nearly as efficient as conventional nuclear p53 in killing primary lymphoma cells in the animal (Table 1) . Conversely, normal cells from thymus, spleen and bone marrow showed poor infectivity with these retroviruses (Talos et al., 2005) . Together, these studies significantly take forward the notion that the direct mitochondrial p53 program, which executes the shortest known circuitry of p53 death signaling, might also be exploited for inducing apoptosis in mutant p53 tumor cells in vivo. Such studies are currently underway. In p53-targeted therapeutics research, up to now efforts focused on restoring transcription-mediated p53-dependent apoptosis. One venue tries to identify small molecules such as CP-31398 and PRIMA-1 that structurally rescue tumor-derived p53 mutant proteins (Foster et al., 1999; Bykov et al., 2002) . Another venue focuses on supplying conventional wtp53 via gene therapy (Moll, 2000) . For example, adenovirus-based conventional p53 gene therapy was recently approved by the Chinese Food and Drug Administration for patients with head and neck squamous cell carcinoma and is also in late-stage clinical trials in China and in the West for other malignancies (Zeimet and Marth, 2003; Peng, 2005) . Both the wtp53 and small molecule approach have in common that they rely on the preserved ability of tumor cells to respond with transcriptional activation of p53 target genes. However, many human cancers have lost this prerequisite due to global epigenetic deregulation of their genome, leading to broadly aberrant gene silencing patterns (Herman and Baylin, 2003) . Indeed, conventional p53 gene therapy did fail in ovarian cancer (Zeimet and Marth, 2003) . Fortunately, apoptosis relies upon a preassembled death machinery of protein and DNA degrading enzymes that do not require transcription of new genes. Our study in the Em-Myc lymphoma system shows that at least in principle, transcriptional p53 restoration is dispensable for p53-based tumor killing in vivo. As mitochondrial p53 does not require tetramerization for its killing action (Marchenko et al., 2000) , another potential advantage might be its escape from dominant negative interference by endogenous mutant p53 proteins and/or DNp63/p73 isoforms that are commonly overexpressed in tumors. Taken together, there is ample rationale for further studies that investigate its possible therapeutic value, perhaps as a synergistic modality with existing p53-based strategies or conventional anticancer therapy.
New avenues
We and others showed earlier that a small subfraction of stress-induced endogenous mitochondrial p53 localizes within the mitochondria, rather than on the surface, and is found in complex with the major mitochondrial import proteins mt hsp70 and mt hsp60 (Marchenko et al., 2000; Dumont et al., 2003) . This suggests an additional intramitochondrial function of p53 distinct from the Bcl2 family-based OMM permeabilization.
Progress in this direction came from evidence for a possible role of p53 in maintaining the stability of the mitochondrial genome (mtDNA) via the ability to translocate to mitochondria and interact with mtDNA polymerase gamma (pol gamma; specific for mitochondria) (Achanta et al., 2005) . This was seen in response to mtDNA damage by ethidium bromide. In contrast to nuclear DNA, mitochondrial DNA is not packaged in chromatin and nucleosomal particles, but associates with the mitochondrial inner membrane on the matrix side, forming mtDNA-protein nucleoids (Bogenhagen et al., 2003) . p53 enhances the DNA replication function (processivity) of pol gamma in vitro. Loss of p53 results in a significant increase in mtDNA vulnerability to genotoxic damage, leading to increased frequency of mtDNA mutations in cells. This effect can be rescued by p53 expression (Achanta et al., 2005) . Further support for a potential role of p53 in modulating mitochondrial DNA repair exists, specifically mitochondrial base excision repair (BER). In an in vitro uracil incorporation assay that measures flux through the entire BER pathway, the mitochondrial pol gamma gap-filling activity was mildly but reproducibly decreased in p53 knockout extracts, which could be complemented to wild type levels by recombinant p53 (de Souza-Pinto et al., 2004). Moreover, stress-induced mitochondrial p53 engages in endogenous complexes with mitochondrial transcription factor A (mtTFA), the most abundant protein in the mtDNA nucleoids and required for transcription and maintenance of mtDNA. It is tempting to speculate that this p53 complex influences the repair activity of mtTFA, particularly in the context of cisplatin and oxidized mtDNA damage (Yoshida et al., 2003) . However, since mtTFA knockout mice have an increased apoptosis phenotype, this interaction might also somehow play a role in regulating apoptosis. Along these lines, mitochondrial ribosomal protein L41 (MRPL41) is reported to enhance p53 translocation to mitochondria and stabilize p53, thereby contributing to apoptosis (Yoo et al., 2005) . Intramitochondrial p53 might possibly also contribute to apoptosis by making it harder for the cell to counteract damaging reactive oxygen species (ROS) generated by stressed mitochondria at an increased rate. This idea is supported by the observation that in TPA-treated epidermal cells endogenous wtp53 translocates to mitochondria within 10 min (preceding nuclear accumulation) where it reportedly sequesters the major oxidative defense enzyme manganese superoxide dismutase (MnSOD), located in the mitochondrial matrix. This might lead to mitochondrial dysfunction and apoptosis (Zhao et al., 2005) . The precise mechanism and significance of many of these interactions, however, remains to be defined.
Nur77
Nur77 (also known as TR3, NGFI-B, TIS1 and NAK-1) (Lim et al., 1987; Hazel et al., 1988; Milbrandt, 1988; Chang et al., 1989 ) is a transcriptional factor belonging to the superfamily of nuclear receptors. All members of the superfamily share a highly conserved structural organization with an amino-terminal region encoding activation function 1 (AF-1), followed by the DNAbinding domain (DBD), and the ligand-binding domain (LBD). The C-terminal region also encodes activation function 2 (AF-2) (Figure 3) (Kastner et al., 1995; Mangelsdorf and Evans, 1995) . Recent studies have demonstrated that the AF-1 plays a major role in mediating Nur77 transactivation, while AF-2 is dispensable (Wansa et al., 2002 (Wansa et al., , 2003 . Nur77 and the closely related proteins Nurr1 (also known as RNR-1, TINUR, and HZF-3) and NOR-1 (MINOR, CHN, and p53 and Nur77/TR3 UM Moll et al TEC) form a distinct subfamily within the nuclear receptor superfamily (Ferri and Kroemer, 2001; Zhang, 2002; Hsu et al., 2004; Martinez-Gonzalez and Badimon, 2005) , and they are classified as orphan receptors because no physiological ligands for these receptors have been identified (Kastner et al., 1995; Mangelsdorf and Evans, 1995) . Structural analysis of the LBDs of Nurr1 and the Drosophila ortholog of Nor-1, DHR38, reveals no classical ligand-binding pockets in these receptors (Baker et al., 2003; Wang et al., 2003) , suggesting that the biological functions of the Nur77 subfamily are regulated by ligand-independent mechanisms. Nur77 is unique among nuclear receptors in that it is also an immediate-early gene induced by a diversity of extracellular stimulation, ranging from survival, differentiation and apoptosis. They work via distinct modes of action, and account for diverse biological activities of Nur77.
Nur77 as a survival factor
Nur77 was originally identified as a growth factorinducible gene (Lim et al., 1987; Hazel et al., 1988; Milbrandt, 1988; Chang et al., 1989) . It is often overexpressed in a variety of cancer cells, including lung, prostate, breast and colon cancer (Uemura and Chang, 1998; Wu et al., 2002a, b; Jeong et al., 2003; Holla et al., 2005; Maddika et al., 2005) . A number of growth factors and mitogens can potently and rapidly induce the expression of Nur77 in a variety of cancer cells. In prostate tissue, Nur77 is highly expressed in cancer as compared to adjacent normal or benign tissues (Uemura and Chang, 1998) . These observations suggest that Nur77 acts to mediate the growth of cancer cells. By now, compelling evidence has established the survival and oncogenic activities of Nur77 in cancer cells. Ectopic expression of Nur77 stimulates cell cycle progression and proliferation in lung cancer cells through its transcriptional activity (Kolluri et al., 2003) . A recent expression profiling reveals that levels of Nur77 subfamily members are significantly downregulated in the nontransformed HeLaHF revertants, as compared with parental HeLa cells (Ke et al., 2004) . Suppression of Nur77 expression inhibits the transformation phenotype of several cancer lines of different origins by promoting their apoptosis (Ke et al., 2004) . The oncogenic potential of the Nur77 subfamily members is also suggested by the finding that Nor-1 (TEC) is involved in the t(9, 22) chromosomal translocation in extraskeletal myxoid chondrosarcoma (Labelle et al., 1995; Labelle et al., 1999) . The resulting fusion protein, EWS/TEC, is potentially oncogenic, and it is much more active than the native receptor in transactivating target promoters, suggesting that transcriptional activation of Nor-1 is associated with oncogenicity.
Nur77 confers growth advantage on cancer cells by suppressing the negative growth regulatory effect of retinoids. In lung cancer cells, overexpression of Nur77 correlates with their resistance to retinoic acid treatment (Wu et al., 1997b; Chen et al., 2002) , due to Nur77's inhibition of the expression of retinoic acid receptor b (RARb), a growth suppressor of cancer cells (Zhang, 2002) . Nur77 inhibits RARb expression by interacting with retinoid X receptor (RXR) (Wu et al., 1997a) or orphan receptor COUP-TF (Wu et al., 1997b) . Nur77 induced under hypoxic conditions stabilizes and transactivates hypoxia-inducible factor-1a (Yoo et al., 2004) , a protein implicated in tumor aggressiveness, vascularity, treatment failure, and mortality. Consistently, VEGF has been shown to induce the expression of the Nur77 family genes in endothelial cells . Interestingly, Nur77 family members are found as NF-kB-responsive genes in macrophage (Pei et al., 2005a) , controlling expression of cyclin D2 (Pei et al., 2005b) . Overexpression of Nur77 also blocks cell death induced by ceramide in A20 B cell line (Bras et al., 2000) and protect fibroblasts from undergoing tumor necrosis factor-induced cell death (Suzuki et al., 2003) . Induction of Nur77 by hepatitis B virus X protein may play a role in viral carcinogenesis (Lee et al., 2001) . The survival function of Nur77 family members in vivo is well established in the central nervous system. Knockout of Nurr1 in mice results in impaired development and maintenance of midbrain dopaminergic neurons (Zetterstrom et al., 1997), while overexpression of Nurr1 increases the resistance of neural stem cells to neurotoxins (6-hydroxy-dopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine) (Le et al., 1999) .
Nur77 as a death factor
The role of Nur77 in apoptosis was first recognized in 1994, showing that Nur77 is inducible by T-cell receptor signals and that Nur77 expression is high during T-cell receptor-mediated apoptosis (Liu et al., 1994; Woronicz et al., 1994) . Inhibition of Nur77 function by a dominant-negative Nur77 blocks T-cell receptormediated apoptosis in thymocytes and their negative selection, whereas thymocytes from Nur77-expressing transgenic mice show massive apoptosis. However, Nur77 knockout mice do not exhibit any defect in thymocyte apoptosis (Cheng et al., 1997b) , suggesting a possible functional redundancy among Nur77 family members.
The apoptotic effect of Nur77 in cancer cells was discovered during investigations of the apoptotic effect of the retinoid-related molecule AHPN (also called CD437; 6-(3-(1-adamantyl)-4-hydroxyphenyl)-2-naphtha-lenecarboxylic acid) (Li et al., 1998) . AHPN/ CD437, currently being evaluated in clinical trials as anticancer agent, causes growth arrest and apoptosis in p53 and Nur77/TR3 UM Moll et al epithelial cancer models in vitro and in vivo (Costantini et al., 2000; Fontana and Rishi, 2002; Zhang, 2002; Lotan, 2003; Pfahl and Piedrafita, 2003; Holmes et al., 2004) . Although highly complex in its pro-apoptotic actions, in CA-OVOC3 ovarian cancer cells AHPN/ CD437 kills through a signaling pathway independent of retinoid receptor activation. Instead, it induces Nur77 transcription by signaling through MEK, p38MAP kinase and MEF2 (a transcription factor inducing Nur77) (Holmes et al., 2003b) . Inhibition of Nur77 expression by antisense RNA prevents the apoptotic effect of AHPN/CD437. Rapid induction of Nur77 also occurs in cancer cells after stimulation of apoptosis by a variety of apoptosis-inducing agents, including calcium ionophores, etoposide (VP-16) (Li et al., 2000; Liu, 2002) , and phorbol ester (Li et al., 2000; Liu, 2002; Cao et al., 2004a; Lin et al., 2004b) , synthetic chenodeoxycholic acid derivatives (Jeong et al., 2003) , Di-n-butyltin dichloride (Gennari et al., 2002) , histone deacetylase inhibitors (Chinnaiyan et al., 2006) , cadmium (Shin et al., 2004) , 1,1-bis(3 0 -indolyl)-1-(p-substituted phenyl)-methanes (Chintharlapalli et al., 2005) , and induced Nur77 contributes to their apoptotic effects.
The apoptotic effect of Nur77 appears to be clinically relevant as a recent study shows that the expression of the Nur77 subfamily member Nor-1 is positively correlated with survival in diffuse large B-cell lymphoma patients treated with the drugs cyclophosphamide, adriamycin and vincristine (Shipp et al., 2002) . In addition, gene expression profiles of tumor samples obtained from various cancer patients reveal that downregulation of Nur77 is associated with metastasis of primary solid tumors, including lung cancer, breast cancer and prostate cancer (Ramaswamy et al., 2003) .
Transcriptional regulation by Nur77
Although Nur77 expression is induced by a diversity of signals, our knowledge of its molecular mechanism of action is very limited. Like most nuclear receptors, Nur77 binds to specific DNA sequences as homodimers or heterodimers (Ferri and Kroemer, 2001; Zhang, 2002; Hsu et al., 2004; Martinez-Gonzalez and Badimon, 2005) . In addition, Nur77 can bind DNA as monomers. Despite the identification of Nur77-binding sequences and the accumulating evidence that Nur77 functions to mediate the biological responses of a variety of extracellular stimuli, very few Nur77 direct target genes have been identified. Regulation of tyrosine hydroxylase expression by Nurr1, presumably through its monomer binding, may be important for Nur77 family member action in the central nervous system (Sakurada et al., 1999) . The promoter of pituitary pro-opiomelanocortin (POMC) gene contains a Nur-response element (NurRE) that binds Nur77 homodimers, supporting transcriptional modulation by Nur77 of the hypothalamo-pituitary-adrenal axis (Philips et al., 1997) . Nur77 can also bind DNA as a heterodimer with retinoid X receptor (RXR) (Forman et al., 1995; Perlmann and Jansson, 1995) , which can be activated by RXR ligands, providing an opportunity to regulate Nur77 activity using small molecules. Nur77/RXRa heterodimers bind to the RA response element (RARE) in the RARb promoter, thereby promoting RARb expression by RXR ligand (Wu et al., 1997a; Chen et al., 2002) . Nur77 can also heterodimerize with orphan receptor COUP-TF (Wu et al., 1997b) to regulate the expression of RARb. As RARb plays a key role in growth, survival, differentiation and apoptosis of various cell types, regulation of RARb expression may account for diverse biological activities of Nur77 family members.
Nur77-induced apoptosis is rapid and robotic. Like in the case of p53, Nur77 is thought to exert its proapoptotic action, at least in part, through its nuclear transactivation of gene expression. However, attempts to identify downstream transcriptional targets of Nur77 in this process have had only limited success. Transactivation of RARb expression by the Nur77/RXRa heterodimer is critical for apoptosis induction (Wu et al., 1997a) . A significant amount of work has been conducted in T cells. FasL was initially considered to be the potential downstream targets of Nur77, based on the observation that their expression is elevated in Nur77 transgenic mice (Weih et al., 1996) . However, subsequent studies showed that overexpression of Nur77 does not lead to any induction of FasL expression (Cheng et al., 1997b) , and Nur77-mediated apoptosis is intact in mice carrying the FasL mutation (Cheng et al., 1997b) . Microarray analysis using RNA isolated from Nur77 transgenic and wild-type fetal thymi demonstrates that two novel genes, NDG1 and NDG2, are induced by Nur77 expression (Rajpal et al., 2003) . NDG2 targets mitochondria, but its role in apoptosis remains to be defined. In contrast, NDG1 exhibits apoptotic activity independent of the death receptor pathway, involving activation of caspase-8 and -3. However, it remains to be seen whether both NDG1 and NDG2 are direct transcriptional targets of Nur77. Further, expression of NDG1 in T cells does not lead to massive apoptosis, in contrast to Nur77 (Rajpal et al., 2003) , suggesting that other Nur77-mediated apoptotic events are involved in Nur77-induced T-cell apoptosis. In this regard, in thymic lymphoma ionomycin-induced Nur77 DNA-binding does not cause apoptosis. In contrast, prevention of ionomycin-induced Nur77 DNA binding by either calcineurin inhibitor FK506 or serine/threonine protein kinase inhibitor HA1004 results in extensive apoptosis (Kochel et al., 2005) . It would, therefore, be important to test whether DNA binding of Nur77 is required for apoptosis in normal thymocytes in a physiological setting.
Mitochondrial targeting as a mechanism for initiating apoptosis
While there is a correlation between transcriptional function of Nur77 and apoptosis in T cells, evidence for the role of Nur77 transactivation in apoptosis of cancer cells is lacking. Mu and Chang (2003) showed that TR3/ Nur77 induces E2F1 expression by binding to the TR3 p53 and Nur77/TR3 UM Moll et al response element (TR3RE) in the E2F1 promoter region. Although antisense E2F1 partially rescues the TR3/Nur77-mediated cell apoptosis, E2F1 induction by Nur77 may mainly contribute to its regulation of cycle progression .
Several lines of evidence suggest mechanisms other than transcriptional regulation for Nur77-induced apoptosis. Unlike many other members of the nuclear receptors that are localized in the nucleus and bind to DNA in the absence of their ligand, Nur77 resides predominantly in the cytoplasm in many cell types (Fahrner et al., 1990; Hazel et al., 1991; Davis et al., 1993; Woronicz et al., 1995) . As biological activities of Nur77 are highly regulated through phosphorylation, heavily phosphorylated Nur77 is located in the cytoplasm, while hypophosphorylated Nur77 is primarily localized in the nucleus (Fahrner et al., 1990) . The fact that the apoptosis-inducing agents PMA and inomycin phosphorylate Nur77 (Fahrner et al., 1990) suggests that phosphorylated Nur77 forms may be localized at mitochondria. PMA and ionomycin phosphorylate Nur77 at Ser354 in the A-box of its DNAbinding domain (Woronicz et al., 1995) , an event known to abolish its DNA-binding activity (Davis et al., 1993; Hirata et al., 1993) , suggesting that DNA binding is not required for Nur77-induced apoptosis. Similarly, although Nur77 expression is required for apoptosis induction by several apoptotic stimuli, Nur77 transactivation is inhibited by these apoptotic stimuli (Li et al., 2000) .
Unlike T cells, where overexpression of Nur77 leads to massive apoptosis (Cheng et al., 1997b; Liu et al., 1994; Woronicz et al., 1994) , cancer cells often exhibit enhanced survival and proliferation upon Nur77 overexpression. In H460 lung cancer cells, overexpression of Nur77 leads to an enhanced cell proliferation and cell cycle progression (Kolluri et al., 2003) . Similarly, overexpression of Nur77 in HeLa cells and other cancer cells promotes their survival (Ke et al., 2004) . Many growth factors trigger cell survival programs through induction of Nur77. Thus, Nur77 must engage discrete regulatory mechanisms to accomplish its apoptotic effect in cancer cells. Additional complexity of the death effect of Nur77 comes from recent results showing that Nur77 regulates distinct death programs depending on cell type and death stimuli. Nur77-induced apoptosis involves the mitochondrial pathway in many cancer cells (Ferri and Kroemer, 2001; Zhang, 2002) . In contrast, release of cytochrome c is not detected in apoptotic thymocytes from Nur77 transgenic mice (Rajpal et al., 2003) . Moreover, Nur77 mediates an alternative, nonapoptotic programmed cell death in response to activation of neurokinin-1 receptor by Substance P via ERK2 activation (Castro-Obregon et al., 2004) . Another variation of pro-apoptotic Nur77 action was reported specifically for colon cancer cells. Here, as opposed to the prototypical prostate cancer cells, Nur77 translocates to the cytoplasm but not directly to mitochondria upon various apoptotic stimuli (fatty acid butyrate, the non-steroidal anti-inflammatory sulindac or 5-FU). Instead, translocation-dependent indirect activation of the mitochondrial pathway via Bax relocalization is proposed (Wilson et al., 2003) .
These observations indicate that Nur77 can employ different mechanisms to initiate apoptosis depending on cell type and death stimuli.
Accumulating evidence demonstrates that translocation of Nur77 from the nucleus to mitochondria represents an important mechanism by which Nur77 initiates apoptosis (Figure 4) . In response to several apoptotic stimuli, Nur77 migrates from the nucleus to the cytoplasm, where it targets mitochondria (Li et al., 2000) . Mitochondrial localization of Nur77 is associated with release of cytochrome c from mitochondria and apoptosis. Interestingly, DNA-binding domain-deleted Nur77 constitutively resides at mitochondria and is accompanied by extensive cytochrome c release (Li et al., 2000; Holmes et al., 2003b; Lin, 2004) . The Nterminal AF-1 region is also dispensable for Nur77 mitochondrial targeting and apoptosis (Lin, 2004) . Thus, DNA-binding and transactivation of Nur77 are not required for apoptosis induction by Nur77. In contrast, the cytoplasmic localization of Nur77 and its mitochondrial localization are essential for its apoptotic effect. Nuclear retention of Nur77 or re-targeting of Nur77 to the plasma membrane or the endoplasmic reticulum membrane abrogates its ability to induce cytochrome c release (Li et al., 2000) .
The apoptosis-associated nuclear egress of Nur77 has now been observed in cancer cells from lung, ovary, colon, prostate, stomach and breast. In CA-OV-3 ovarian cancer cells, Nur77 translocates from the nucleus to mitochondria in response to AHPN/CD437 treatment (Holmes et al., 2003a (Holmes et al., , b, 2004 , similar to its effect in LNCaP prostate cancer (Li et al., 2000; Lin, 2004) and H460 lung cancer cells (Dawson et al., 2001; Kolluri et al., 2003; Cao et al., 2004a; Lin, 2004) . Insulin-like growth factor-binding protein-3 (IGFBP-3)-induced apoptosis in 22RV1 prostate cancer cells is accompanied by Nur77 mitochondrial targeting , while Nur77 mitochondrial targeting is an important mechanism for apoptosis of gastric cancer cells in response to diverse apoptotic stimuli, including AHPN/CD437 (Lin, 2004) , TPA, VP-16 (Liu, 2002; Wu et al., 2002a) , and several synthetic chenodeoxycholic acid derivatives (Jeong et al., 2003) . Nur77 mitochondrial localization is also involved in Sindbis virusinduced apoptosis (Lee et al., 2002 , which is prevented by Epstein-Barr virus nuclear antigen EBNA2 through its interaction with Nur77. Cancerspecific toxicity of apoptin, a small prolin-rich protein derived from the chicken anaemia virus, triggers cytochrome c release in MCF-7 breast cancer cells by inducing Nur77 migration to mitochondria (Maddika et al., 2005) . Nur77 mitochondrial targeting also plays a role in neuronal cell death. Nur77 rapidly translocates to mitochondria in cerebellar granule neurons exposed to glutamate, which is blocked by EGF through its activation of ERK2 (Jacobs et al., 2004) . We have also observed that neurotoxin causes extensive mitochondrial localization in dopaminergic neurons (Zhang et al., unpublished results) . Thus, Nur77 mitochondrial targeting may play a role in the development of neurodegenerative diseases.
Conversion of Bcl2 from an anti-apoptotic to a pro-apoptotic molecule by Nur77
Like p53, Nur77 lacks classical mitochondrial-targeting sequences. Studies of its mechanism of mitochondrial targeting reveals that Bcl2, with its ability to interact with Nur77, functions as a mitochondrial receptor of Nur77 (Lin, 2004) (Figure 4 ). Nur77 interaction with Bcl2 represents the first example that a nuclear receptor interacts with a Bcl2 family member, providing the coupling of Nur77 nuclear receptor signaling to the Bcl2-mediated apoptotic machinery. In this regard, Bcl2 does not act as an anti-apoptotic protein in Nur77-mediated apoptosis. Instead, the interaction between Nur77 and Bcl2 triggers cytochrome c release and apoptosis (Lin, 2004) . The Nur77-Bcl2 interaction conformationally converts Bcl2 from an anti-apoptotic to a pro-apoptotic molecule, providing a new approach to switch the Bcl2 phenotype. It remains to be seen whether other Bcl2 family members interact with Nur77, mediating its mitochondrial targeting and apoptosis.
The interaction of Nur77 with Bcl2 and subsequent conversion of the Bcl2 phenotype provide an explanation for the opposing phenotypes of some Bcl2 family members. For example, overexpression of Bcl2 in some cell types promotes rather than prevents apoptosis (Cheng et al., 1997a; Grandgirard et al., 1998; Uhlmann et al., 1998; Subramanian and Chinnadurai, 2003) . Conversely, overexpression of Bax is cytoprotective rather than cytodestructive in some cell types under some circumstances (Lewis et al., 1999; Fannjiang et al., 2003) . Similarly, mutants of the Bcl2 homolog Ced-9 appear to promote rather than prevent apoptosis in Caenorhabditis elegans (Xue and Horvitz, 1997) . Likewise, Bcl2 homologs in Drosophila can manifest either cytoprotective or cytodestructive phenotypes, depending on the cellular context (Igaki et al., 2000) . The opposing biological activities may account for some clinical observations that overexpression of Bcl2 is associated with a favorable prognosis (Gasparini et al., 1995; Daidone et al., 1999; Catz and Johnson, 2003; Martin et al., 2003) . For breast cancer, high Bcl2 levels are associated with markers of favorable prognosis, such as the expression of hormone nuclear receptors, low tumor grade and responsiveness to endocrine therapy (Daidone et al., 1999) . A recent systematic review of the literature shows that overexpression of Bcl2 is also a good prognostic factor for survival in patients with non-small lung cancer (Martin et al., 2003) .
An important question is how Bcl2 is converted into a killer by Nur77 binding. All members of the Bcl2 family possess at least one of the four conserved BH domains (Reed, 1998; Cory et al., 2003) . Anti-apoptotic Bcl2 family members Bcl2 and BclXL have hydrophobic pockets on their surfaces, which is essential for their anti-apoptotic effect, while their BH3 domains are buried. In contrast, pro-apoptotic Bcl2 family members have an exposed BH3 domain, which bind to the hydrophobic pockets of anti-apoptotic Bcl2 members (made up by their BH1, BH2 and BH3 domains) to inhibit their survival effect. The unstructured loop region of B50 amino acid length located between the BH4 (a1 helix) and BH3 (a2 helix) domains of Bcl2 plays an important, albeit highly complex role in regulating Figure 4 The Nur77-Bcl2 apoptotic and survival pathways. In response to growth stimuli, Nur77 acts as a transcription factor to positively regulate expression of genes involved in cell proliferation. Nur77 is also induced by certain apoptotic stimuli, and upon appropriate modification (probably by phosphorylation), migrates from the nucleus to the cytoplasm as Nur77/RXRa heterodimer, where it targets mitochondria by binding to Bcl2. Interaction with Bcl2 induces a Bcl2 conformational change, triggering cytochrome c release and apoptosis.
p53 and Nur77/TR3 UM Moll et al Bcl2 functions. Deletion of the loop region of Bcl2 blocks paclitaxel-induced apoptosis (Srivastava et al., 1999) , whereas caspase-mediated cleavage within the loop region of Bcl2 converts it into a pro-apoptotic molecule (Cheng et al., 1997a; Grandgirard et al., 1998) . Modification of the loop region of Bcl2 or BclXL by phosphorylation or deamidation is associated with downregulation of their anti-apoptotic activity (Haldar et al., 1995; Yamamoto et al., 1999; Deverman et al., 2002) . Upon Nur77 binding to the loop of Bcl2, the hydrophobic binding groove of Bcl2 undergoes an extensive rearrangement, resulting in exposure of its BH3 domain (Lin, 2004) . This conformational change is responsible for the conversion of Bcl2 from a cytoprotective to a cytodestructive molecule. It is likely that proapoptotic Bcl2 acts as a BH3-only protein to regulate the apoptotic potential of other Bcl2 family members. Activation of Bax or Bak requires their binding to BH3-only protein tBid (Wei et al., 2000 (Wei et al., , 2001 .
Regulation of Nur77 mitochondrial targeting by RXR and its ligands
A notable feature of nuclear receptors is that they undergo extensive homo-and heterodimerization via a domain located within the LBD that typically greatly enhances their DNA binding and transactivation. RXRs are particularly potent and promiscuous heterodimerization partners for many nuclear receptors including Nur77, facilitating their DNA binding and nuclear localization. This is partly due to the fact that they have two dimerization domains, a strong one in the LBD and a weak one in the DBD.
Nur77 lacks a classical ligand-binding pocket. However, RXR and its ligands are critical regulators of Nur77 activities through heterodimerization. RXRa serves as the switchable shuttler for Nur77 mitochondrial targeting (Cao et al., 2004b; Lin et al., 2004a, b) . In the nucleus, Nur77/RXR heterodimers bind and activate the DR-5 promoter response element in response to certain RXR ligands (Forman et al., 1995; Perlmann and Jansson, 1995; Wu et al., 1997a) . This might provide a mechanism to modulate Nur77's survival activity by RXR ligands, such as synthetic retinoids and polyunsaturated fatty acids (de Urquiza et al., 2000; Fan et al., 2003; Goldstein et al., 2003; Lengqvist et al., 2004) , in cancer and in neurons.
Nur77 nuclear export and mitochondrial targeting requires RXR heterodimerization (Cao et al., 2004b; Lin et al., 2004a, b) . Nur77 and RXR engage in an interesting job sharing. Nur77, despite possessing a classical nuclear export signal (NES) used in differentiation signaling (Katagiri et al., 2000) , is the passive partner in transport but the acting partner in mediating mitochondrial apoptosis. Nur77 export is mediated via CRM1 receptors by a strong NES located in the LBD of RXRa, which is conformationally regulated by ligand binding. In response to apoptotic stimuli, Nur77 and RXRa associate with mitochondria as a Nur77/RXRa heterodimer, as seen in LNCaP prostate cancer, H460 lung cancer cells and in MGC80-3 gastric cancer cells . Conversely, RXR prevents EGF-induced nuclear accumulation of Nur77 (Jacobs and Paulsen, 2005) .
As RXR activities are regulated by its ligands, it is not surprising that RXR modulates Nur77 subcellular localization in a ligand-dependent manner. However, controversy exists with respect to the precise export mechanisms (CRM1 dependence) and regulatory effect of RXR ligands. Cao et al. (2004b) found that in the presence of RXR transactivation agonists (ligands) such as 9-cis-RA, Nur77/RXRa heterodimers form via dimerization sites in their LBDs, resulting in chromatin-binding heterodimers with efficient transactivation of retinoic acid response genes. This concomitantly silences the NES, thus fortifying nuclear localization. In accord, RXR transcriptional agonists suppress apoptosis by inhibiting mitochondrial targeting (Cao et al., 2004b) . 9-cis-RA also relieves the inhibitory effect of RXR on EGF-induced Nur77 nuclear accumulation (Jacobs and Paulsen, 2005) and could account for the inhibitory effect of RXR ligands on apoptosis. For example, 9-cis-RA potently inhibits the activationinduced apoptosis of T cells and thymocytes (Bissonnette et al., 1995; Yang et al., 1993 Yang et al., , 1995 , in which Nur77 plays a role. The inhibitory effect of 9-cis-RA was enhanced in T-cell hybridomas overexpressing RXRb, but attenuated in cells overexpressing dominant-negative RXRb (Yang et al., 1995) .
In the absence of ligand and (the simultaneous presence of certain apoptotic stimuli), however, Cao et al. (2004b) found that Nur77/RXRa heterodimers are formed via dimerization sites in their DBDs. Here, NES is active and mediates mitochondrial targeting and apoptosis. It is unknown how an apoptotic stimulus activates the RXRa NES, but such stimuli possibly regulate the dimerization interface switch through modulation of receptor phosphorylation. This is consistent with recent observations that Akt, a potent antiapoptotic kinase, phosphorylates Nur77 at amino acids lat the C-terminal extension, which is important for its protein-protein interaction (Meinke and Sigler, 1999; Cao et al., 2004a) .
In contrast, Lin et al found a positive 9-cis-RA effect. In their hands, 9-cis-RA was required to induce the RXR-mediated nucleo-cytoplasmic shuttling of Nur77 and its translocation to mitochondria to induce apoptosis (Lin, 2004) . Such an effect of 9-cis-RA appears to be contradictory to its known transcriptional activation of RXR. Given the unstable nature of 9-cis-RA, it is likely that a 9-cis-RA metabolite may act to induce RXR nuclear export. Such a RXRa ligand may induce the nuclear export of Nur77/RXR heterodimers by modulating their heterodimerization. In this regard, the NSAID R-etodolac binds RXRa and acts as a RXRa antagonist to inhibit its transactivation, an event which is associated with its tumor-selective induction of apoptosis in animals (Kolluri et al., 2005) . Several dietary fatty acids, including DHA (de Urquiza et al., 2000) , are also known to bind to RXR. It remains to be seen whether other NSAIDs and fatty acids exert their p53 and Nur77/TR3 UM Moll et al anti-cancer effects by modulating Nur77 mitochondrial targeting through their binding to RXRa. Nur77/RXR heterodimerization and the activation of its NES are also subjected to regulation by other binding proteins. Binding of RXR to IGFBP-3 allows a rapid translocation of Nur77/RXR heterodimers to mitochondria, initiating an apoptotic cascade , whereas binding of Nur77 to EBNA2 prevents their nuclear export .
Regulation of Nur77 mitochondrial targeting by phosphorylation
Recent studies showed that phosphorylation also regulates Nur77 subcellular trafficking. Nur77 mitochondrial targeting is induced by apoptotic retinoid-related compounds, TPA, a calcium ionophore, and chemotherapeutic agents, which are known to act through membrane-signaling pathways involving various kinases and phosphatases. Consistently, Nur77 is heavily phosphorylated in various cell types (Li et al., 2000; Kolluri et al., 2003; Han et al., 2006) . Nur77 is phosphorylated at its N-terminal A/B domain by c-Jun-N-terminal kinase (JNK) (Kolluri et al., 2003; Han et al., 2006) , ERK2 (Jacobs et al., 2004 (Jacobs et al., , 2005 Slagsvold et al., 2002) , and the MAP kinase pathway (Katagiri et al., 2000) . It is also phosphorylated at Ser350 (Ser351 in human Nur77) by Akt (Masuyama et al., 2001; Pekarsky et al., 2001 ) and p90-kDa ribosomal S6 kinase (RSK) (Chen and Blenis, 1990; Chen et al., 1991; Swanson et al., 1999; Wingate et al., 2005) , a Serine/Threonine protein kinase and a downstream effector of MAPK.
The Nur77 N-terminal A/B region is the major domain responsible for regulation by phosphorylation. About 30% of amino acids in this region are potential sites for phosphorylation. Deletion of the N-terminal region abrogates the effect of apoptotic stimuli on Nur77 mitochondrial targeting (Li et al., 2000) , indicating their important regulatory role. NGF-induced NGFI-B nuclear export requires the phosphorylation of NGFI-B at Ser105 by the MAP kinase pathway (Katagiri et al., 2000) . In contrast, glutamate-induced Nur77 mitochondrial targeting is inhibited by EGF through its activation of ERK2 that phosphorylates Thr142 of NGFI-B (Jacobs et al., 2004) . JNK positively regulates Nur77 nuclear export and apoptosis by phosphorylating Nur77 N-terminal amino acid residues (Han et al., 2006) . Inhibition of JNK activation by a JNK inhibitor abolished AHPN/CD437 analog 3-Cl-AHPC-induced Nur77 nuclear export. Consistently, other apoptotic stimuli including TPA, VP16, and cisplatin, which induce Nur77 nuclear export, are known to activate JNK. However, JNK activation alone is insufficient to induce Nur77 nuclear export. Rather, it may function to inhibit Nur77 nuclear accumulation. Other signaling pathways or proteins are therefore required to complete the process of Nur77 nuclear export.
Recent studies indicate that phosphorylation of Nur77 at Ser351 also influences diverse activities of Nur77, including Nur77 DNA binding, transactivation, Nur77 subcellular localization, and apoptotic activities (Chen and Blenis, 1990; Chen et al., 1991; Swanson et al., 1999; Masuyama et al., 2001; Pekarsky et al., 2001; Wingate et al., 2005) . Ser351 is phosphorylated by different kinases, including Akt and RSK. Akt mediates the anti-apoptotic effects of growth factors through PI3-K and is constitutively activated in many cancer cell lines, confering their survival. Phosphorylation of Nur77 by Akt negatively regulates its nuclear export (Han et al., 2006) , resulting in delayed Nur77 nuclear export. Consistently, deletion of the DBD and Ser351 from Nur77 (called mutant Nur77/DDBD) constitutively targets to mitochondria and induces apoptosis (Li et al., 2000; Kolluri et al., 2003; Lin, 2004) . Thus, phosphorylation of Nur77 by Akt at Ser351 negatively regulates Nur77 nuclear export and Nur77-dependent apoptosis.
Ser351 of Nur77 is also phosphorylated by RSK. ERK2, an upstream activator of RSK, inhibits apoptosis-induced Nur77 nuclear export (Jacobs et al., 2004) , suggesting that phosphorylation of Ser351 by RSK may be responsible for the inhibitory effect of ERK2 on Nur77 nuclear export. TPA-induces Nur77 nuclear export and apoptosis in LNCaP cells. In contrast, in H460 lung cancer cells TPA is unable to induce Nur77 nuclear export (Zhang et al., unpublished) , but strongly activates RSK (Han et al., 2006) , indicating cell type differences in signaling pathways.
Nur77 mitochondrial targeting and cancer therapeutics
As described above, Nur77, a member of the nuclear receptor superfamily of transcriptional factors, is a key regulator of cell proliferation and apoptosis, two important processes that control tumor development. While its transactivation promotes cancer cell growth and may be oncogenic, its translocation into mitochondria mediates apoptotic effects of certain chemotherapeutic agents. Translocation of Nur77 to mitochondria where it converts Bcl2 from a cytoprotective to a killer represents a new paradigm in cancer cell apoptosis (Figure 4) . Although many questions regarding the mechanism regulating Nur77 migration remain, this unique property of Nur77 makes it an attractive molecular target for developing new therapeutics for cancer prevention and treatment. It is increasingly accepted that the efficacy of chemotherapeutic drugs depends largely on their ability to induce apoptosis. Understanding the mechanism governing Nur77-induced apoptosis of cancer cells may provide a molecular basis for the development of new and more effective therapies for cancer and other diseases. In this regard, Nur77 and Bcl2 are of particular interest since they are often overexpressed in cancer cells, providing an excellent opportunity to preferentially induce apoptosis of cancer cells. Targeting the Nur77-Bcl2 pathway should be highly effective in inducing apoptosis, because it engages a simultaneous suppression of an anti-apoptotic effect and activation of an pro-apoptotic effect. Agents that p53 and Nur77/TR3 UM Moll et al induce translocation of Nur77 from the nucleus to mitochondria may inhibit cancer cell growth conferred by the nuclear action of Nur77 and at the same time may induce cancer cell death. Similarly, strategies to increase Nur77 expression could be used in combination with agents that induce its mitochondrial targeting to improve the efficacy of cancer therapy. Recent advances in understanding the mechanisms underlying Nur77 mitochondrial targeting provides several opportunities for identifying such agents. Nur77 translocation to mitochondria as Nur77/RXR heterodimers offers an opportunity to identify RXR ligands for regulating the Nur77-dependent apoptotic pathway.
Mechanistic similarities of the transcription-independent pro-death programs of p53 and Nur77 at mitochondria
In response to apoptotic stimuli, p53 acts as transcription factor in the nucleus to induce the expression of proapoptotic genes. In contrast, Nur77 is a Janus-type protein with pro-and anti-apoptotic actions. When acting as a transcription factor, Nur77 mainly promotes the expression of survival molecules. In the cytoplasm, both p53 and Nur77 proteins mediate apoptosis by targeting directly to mitochondria and binding to antiapoptotic Bcl2 (Nur77) and Bcl2/ BclXL (p53). p53 uses its DNA-binding domain to bind to the 'underside' of BclXL and Bcl2, thereby inhibiting their anti-apoptotic action. In case of BclXL, this has been mapped to the BH4 domain and the two loops between the a3 and a4 and the a5 and a6 helices. Nur 77 binds to the loop region of Bcl2, resulting in a rearrangement of the hydrophobic binding groove of Bcl2 and exposure of its BH3 domain. This binding conformationally converts Bcl2 to a killer that triggers cytochrome c release and apoptosis. The end result in both cases is the homooligomerization of Bax and Bak and mitochondrial membrane permeabilization ( Figure 5 ). (A possible functional interaction between the p53 and Nur77 proteins at mitochondria is purely hypothetical but has not been addressed). Taken together, an accumulating body of evidence provides ample rationale to further investigate how these mitochondrial p53 and Nur77 pathways could become exploitable targets for new cancer therapeutics. Mechanistic similarities of the transcription-independent pro-death programs of p53 and Nur77 at mitochondria. For details see text. In response to apoptotic stimuli, p53 acts as transcription factor in the nucleus to induce the expression of proapoptotic genes. In contrast, Nur77 is a Janus-type protein with pro-and anti-apoptotic actions. When acting as a transcription factor, Nur77 mainly promotes the expression of survival molecules. In the cytoplasm, both p53 and Nur77 proteins mediate apoptosis by targeting directly to mitochondria and binding to anti-apoptotic Bcl2 (Nur77) and Bcl2/ BclXL (p53). Nur 77 binds to the loop region of Bcl2, resulting in a rearrangement of the hydrophobic binding groove of Bcl2 and exposure of its BH3 domain. p53 uses its DNA-binding domain to bind to the 'underside' of BclXL and Bcl2, involving the BH4 domain and the two loops between the a3 and a4 and the a5 and a6 helices in BclXL. The end result in both cases is the homo-oligomerization of Bax and Bak and mitochondrial membrane permeabilization.
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